Elacestrant vs Taragarestrant
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Elacestrant
Marketed by Stemline Therapeutics, Inc. and partners
NCT03778931 · Phase 3 · completed
This was a large randomized trial comparing elacestrant with active standard-of-care treatment, but it was open-label rather than double-blind. The primary progression-free survival endpoints, assessed by blinded imaging review, were statistically significantly better with elacestrant in both ESR1-mutant and all participants, but the lack of participant and investigator blinding limits the strength of the evidence.
Next expected readout: November 2026 · NCT06691035 (registry estimate)
Reported efficacy
Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)); Progression-free Survival in All Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14) (met)
Result source: NCT03778931
Taragarestrant
Developed by InventisBio
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2026 · NCT06954961 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Elacestrant | Taragarestrant |
|---|---|---|
| PFS, median | 3.8 vs 1.9vs Standard of Care (SoC)NCT037789311 other result
| —Trial running · NCT06954961 |
| OS, median | —Trial running · NCT06382948 | —Trial running · NCT06954961 |
| ORR | —Trial running · NCT06382948 | —Trial running · NCT06954961 |
| Clinical benefit rate | —Trial running · NCT06382948 | —Trial running · NCT06954961 |
PFS, median
- Elacestrant
- 3.8 vs 1.9vs Standard of Care (SoC)NCT03778931
1 other result
- 2.8 vs 1.9 NCT03778931
- Taragarestrant
- —Trial running · NCT06954961
OS, median
- Elacestrant
- —Trial running · NCT06382948
- Taragarestrant
- —Trial running · NCT06954961
ORR
- Elacestrant
- —Trial running · NCT06382948
- Taragarestrant
- —Trial running · NCT06954961
Clinical benefit rate
- Elacestrant
- —Trial running · NCT06382948
- Taragarestrant
- —Trial running · NCT06954961
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Taragarestrant: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Elacestrant: 3 of 4 rows · Taragarestrant: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Elacestrant |
|---|---|
| Dropout rate | 36.4% NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Discontinued due to AEs | — NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Serious AEs | 12.2% NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Most frequent reported AEs | nausea 35% fatigue 19% vomiting 19% NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Elacestrant
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elacestrant's landscape · Taragarestrant's landscape